TYK MEDICINES-B

2410
3.3709.53% ( -0.355 )
Delay Closed: Nov 16, 16:08:11

Overview

TYK MEDICINES-B (2410)

TYK Medicines, Inc., a clinical-stage biopharmaceutical company, research, development and commercialization of pharmaceutical products. Its lead product candid...

Open
3.620
High
3.710
Low
3.360
Prev. Close
3.725
Volume
887.50K
Turnover
3.08M
Avg Price
3.470
Bid/Ask Ratio
80.00%
Amplitude
9.40%
52wk High
14.950
Volume Ratio
0.11
Turnover Ratio
0.23%
52wk Low
2.410
HK Mkt Cap
1.28B
Market CapHKD
1.28B
P/ETTM
Loss
P/EDynamic
Loss
P/EStatic
--
EPSTTM
-0.644
EPSDynamic
-0.151
EPSStatic
--
BVPS
0.79
P/B
4.26
HK Shares
380.07M
Dividend YieldTTM
--
DividendTTM
--
Shares
380.07M
Min lot size
500
Currency
HKD

TYK MEDICINES-B Analyst Rating

View more

Forecast & Rating

Apr 29, 2026
Price forecast
HK$24.00612.21%
Forecast & RatingStrong buy
1analysts
  • Strong buy100.00%
  • Buy0.00%
  • Hold0.00%
  • Sell0.00%
  • Strong sell0.00%

Daily Events

  1. Jul, 3

    TYK Medicines opened higher but pulled back during the session, hitting an intraday high of HKD 6.74 before settling at HKD 6.46, up 2.54% from the previous close of HKD 6.30, with total turnover of approximately HKD 31.29 million. The positive move may be linked to the announcement of an extraordinary general meeting on July 30, drawing attention to potential governance changes. However, the stock remains 74.9% below its 52-week high of HKD 25.75 and has fallen 50% year-to-date, while trading below its 60-day moving average of HKD 8.573, with only a 20.75% cushion above the 52-week low. The company narrowed its full-year loss to RMB 300 million with stable R&D spending, secured a drug production license, and had multiple novel cancer programs selected for the AACR meeting, indicating gradual fundamental improvement, though it remains unprofitable with a PB ratio of 7.74.

News